HEMLIBRA
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hemophilia A
Conditions
Hemophilia A
Trial Timeline
Aug 1, 2024 → Jul 18, 2025
NCT ID
NCT05248594About HEMLIBRA
HEMLIBRA is a pre-clinical stage product being developed by Johnson & Johnson for Hemophilia A. The current trial status is completed. This product is registered under clinical trial identifier NCT05248594. Target conditions include Hemophilia A.
What happened to similar drugs?
20 of 20 similar drugs in Hemophilia A were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05248594 | Pre-clinical | Completed |
Competing Products
20 competing products in Hemophilia A
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 40 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 40 |
| Emicizumab + rFVIIa + aPCC | Chugai Pharmaceutical | Phase 3 | 40 |
| Human Coagulation Factor VIII | Chugai Pharmaceutical | Phase 3 | 47 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 47 |
| Emicizumab + Factor VIII (FVIII) | Chugai Pharmaceutical | Phase 3 | 40 |
| Emicizumab | Roche | Phase 3 | 40 |
| Emicizumab | Roche | Phase 3 | 40 |
| Emicizumab | Roche | Approved | 47 |
| Emicizumab | Roche | Phase 3 | 44 |
| SPK-8011QQ | Roche | Phase 1/2 | 39 |
| NXT007 | Roche | Phase 1/2 | 39 |
| Emicizumab Injection | Roche | Phase 2 | 35 |
| Bypassing Agents + FVIII Replacement | Roche | Pre-clinical | 26 |
| PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086 | Pfizer | Phase 2 | 35 |
| Nonacog Alfa (Genetical Recombination) | Pfizer | Pre-clinical | 26 |
| Refacto AF | Pfizer | Pre-clinical | 18 |
| PF-06838435/ fidanacogene elaparvovec | Pfizer | Phase 3 | 44 |
| ReFacto AF | Pfizer | Phase 3 | 40 |
| Nonacog alfa + Nonacog alfa | Pfizer | Phase 3 | 40 |